Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today advises it will release its financial results for the six-month period ending 31 December 2020 (H1 FY2021), on Thursday 25th February 2021. Investors are invited to join a live webcast and Q&A hosted by CEO Dr David Stamler and Chairman Geoffrey Kempler on ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson’s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson’s disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to ...

Highlights: Dr David Stamler appointed CEO; Geoffrey Kempler continues as Non-Executive Chairman New commercial opportunity for PBT2 with UniQuest  to reverse bacterial resistance to antibiotics  US patent for next generation of compounds to treat neurodegenerative disease Phase 2 clinical program underway with commencement of enrollment in BioMUSE natural history study in US for patients with MSA $35M Placement to ...

New hope in global fight against antibiotic resistant superbugs

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) CEO Dr David Stamler will meet with investors during the JP Morgan Healthcare conference, which will run virtually this year from 11th-15th January 2021. Dr Stamler, who was recently appointed CEO of Alterity, is presenting at the HC Wainwright BioConnect and Biotech Showcase events. Both ...

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development.  Mr Geoffrey Kempler, who founded ...